T-cell prolymphocytic leukemia: A single-institution experience

Farhad Ravandi, Susan O'Brien, Dan Jones, Susan Lerner, Stefan Faderl, Alessandra Ferrajoli, William Wierda, Guillermo Garcia-Manero, Deborah Thomas, Charles Koller, Srdan Verstovsek, Francis Giles, Jorge Cortes, Marco Herling, Hagop Kantarjian, Michael Keating

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Background: T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias. Patients and methods: The clinical,pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D. Anderson Cancer Center (MDACC) from 1986 to 2004 were examined. Results: The most common cytogenetic abnormality was inv(14) (q11;q32), which was present in 7 patients. In all 7 patients, this abnormality was associated with other chromosomal aberrations. Patients treated with alemtuzumab at MDACC had a significantly better response rate (P = 0.02) and survival rate (P = 0.002). There were no significant differences in survival based on Tcl-1 expression or different patterns of CD4 and CD8 expression. Conclusion: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.

Original languageEnglish (US)
Pages (from-to)234-239
Number of pages6
JournalClinical Lymphoma and Myeloma
Issue number3
StatePublished - Nov 2005
Externally publishedYes


  • CD52 antigen
  • Deoxycoformycin
  • Fludarabine
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'T-cell prolymphocytic leukemia: A single-institution experience'. Together they form a unique fingerprint.

Cite this